Category - Developments

Developments

Cellectar reports updates on Phase 1 study of iopoffosine I 131 in pHGG

Cellectar Biosciences (NASDAQ: CLRB) announced initial results as of June 10, 2025, from its CLOVER-2 Phase 1 trial evaluating iopoffosine I 131 in relapsed/refractory pediatric high-grade glioma (pHGG) patients...

June 11, 2025

Developments

Adial’s lead AUD candidate advances toward Phase 3 trial

Adial Pharmaceuticals (NASDAQ: ADIL) announced that its lead investigational candidate—AD04—a therapeutic agent for alcohol use disorder (AUD) is progressing toward a Phase 3 trial. According to Adial, as part of its...

June 11, 2025

Developments

Citius and Cardinal sign distribution agreement

Citius Oncology (NASDAQ: CTOR) announced it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH). According to Citius, the agreement is designed to help provide access to LYMPHIR, an...

June 9, 2025

Developments

Leef acquires New York License

Leef Brands (CSE: LEEF; OTCQB: LEEEF) announced it has officially closed on the acquisition of a Type 1 Cannabis Processor License in New York, enabling the company to engage in extraction, blending, infusion...

June 9, 2025

Developments

Aytu signs agreement to commercialize Exxua for MDD

Aytu BioPharma (ASDAQ: AYTU) announced that it has signed an exclusive agreement with closely held Fabre-Kramer Pharmaceuticals to commercialize Exxua—extended-release antidepressant tablets—in the U.S. market for major...

June 9, 2025

Developments

Vaccines publishes key benefits of PharmaJet Tropis ID vaccine over IM SoC

Closely held PharmaJet announced that the results of an implementation research study—titled Evaluating the impact of needle-free delivery of inactivated polio vaccine on Nigeria’s routine immunization program: An...

June 5, 2025

Developments

Perimeter launches OCT-Tissue Registry to power AI and imaging innovation

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced the launch of its optical coherence tomography (OCT)-Tissue Surveillance Registry—a database designed to collect thousands of images from surgical...

June 4, 2025

Developments

Leonard Wheeler, former NFL player, named global ambassador for Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) today announced that it has entered into a consulting agreement with Leonard Wheeler—former NFL player, entrepreneur, author, corporate consultant, co-executive director of the...

June 4, 2025

Developments

Defence opens first U.S. laboratory

Defence Therapeutics (CSE: DTC; OTCQB: DTCFF; FSE: DTC) announced that it has opened its first U.S.-based laboratory in the Boston-Cambridge area. According to Defence, the new laboratory will allow the company to...

June 2, 2025

Developments

atai and Beckley to combine establishing market leader in psychedelic mental health therapies

atai Life Sciences (NASDAQ: ATAI) and closely held Beckley Psytech announced a definitive agreement to combine in an all-share transaction subject to Phase 2b success criteria of BPl-003 in patients with treatment...

June 2, 2025

Category - Developments

Subscribe